In another study where G-CSF was administered to 35/70 patients receiving axi-cel for DLBCL, the severity and incidences of CRS was consistent across both groups, although the duration of CRS was significantly longer in the group of patients who received G-CSF (4.5 days versus 8 days) [53]. The gene discussed is CSF3; the disease is diffuse large B-cell lymphoma.